Testing STP938 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have advanced cancer that cannot be cured with available treatments.
- You have a tumor sample available for testing, and your tumors can be measured on scans.
- You are in reasonably good health (able to do daily activities) and have adequate organ function.
- Side effects from prior treatments have mostly resolved (except hair loss).
- You do not have active brain metastases, uncontrolled infections, or certain heart rhythm issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
This Phase 1/2 study tests dencatistat (STP938) to treat adults whose B-cell or T-cell lymphoma has come back or not responded to treatment. It looks at safety, the best dose, and whether it can shrink tumors or improve disease control when standard options have not helped.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new drug, PTT-936, alone or with other treatments, for people with solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.
This study tests an experimental drug called EP0089 for people with advanced solid tumors that haven't responded to other treatments. It aims to find a safe dose and see if it helps control the cancer.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.